We have combined a proprietary database of single cell genomic data with an AI-powered computational platform that allows us to compare healthy cell development to cancer cell development and map out the drivers of tumorigenesis.
We have assembled a team with deep expertise in cancer biology, medicinal chemistry, and computational science who work closely with leading physician-scientists.
At the center of everything we do are the patients. As pioneers in cancer cell state drug development, we aim to offer patients longer, higher quality lives.
We have fostered a culture that encourages our team to be curious, to think strategically and creatively, and to push the limits of science. We honor diversity and individuality, and are united by a single commitment to serve the patients and families who need new treatments.
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting
Newton, MA, November 5, 2024 – Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present new preclinical data from its lead program AUTX-703 during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition from December 7-10, 2024 in San Diego, CA.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
